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 IV Epoprostenol is a high-risk medication with no
current guidelines for rapid initiation, titration,
and transition from IV to oral therapy. In the
pulmonary arterial hypertension patient
population, successful treatment depends on
individualized patient therapy.
 This patient presented with: worsening
shortness of breath, fatigue and severe
pulmonary hypertension naïve to prostacyclin
therapy, World Health Organization (WHO)
group 1 functional class IV, who was a poor
candidate for IV therapy.
 The preplanned IV to p.o. protocol was initiated
in the ICU setting; the hemodynamics were
monitored via Swan-Ganz catheter. IV
epoprostenol was infused via a central line to a
maximum tolerated dose which allowed for a
higher oral dose to be tolerated; this would not
have been possible with the traditional dosing
schedule.
To target higher oral treprostinil doses rapidly by
using IV epoprostenol preloading.
For the patients whose condition would best be
managed by oral treprostinil rather than IV
epoprostenol therapy, pre-loading the patient using
IV epoprostenol and then rapidly titrating with oral
treprostinil can be done safely and effectively in the
hospital setting to achieve higher dosing with better
side effect management.
Contact Information
Baseline hemodynamics showed markedly
elevated pulmonary pressures, elevated pulmonary
vascular resistance, right ventricular pressure
120/25, pulmonary pressure 120/40, with a mean
of 65, pulmonary wedge pressure 18, cardiac
output 3.35, pulmonary vascular resistance 1066
dynes/sec/cm5, and systemic artery pressure
100/52 mmhg. Hemodynamically the patient
improved over the first night as evidenced by
markedly decreased PA pressures and increased
cardiac output. Swan-Ganz was removed on day 2,
CVP pressure remained elevated at 21 mmhg.
Vitals at discharge were 120/70, heart rate 80 bpm,
O2 98% on 3 liters. The patient was able to tolerate
a rapid initiation, titration, and transition from IV
epoprostenol to a higher dose oral treprostinil
therapy within a shorter time span than the
traditional titration schedule for oral prostacyclin
therapy. Three months following the IV to oral
transition, a right heart catheterization was
completed which showed a 50% reduction in the
pulmonary vascular resistance, to 535
dynes/sec/cm5. The patient experienced mild
nausea, vomiting, and flushing during the
admission, but remained hemodynamically stable.
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FindingsMethodology
 IV epoprostenol was initiated at 2 ng/kg/min with
the goal to increase to 4 ng/kg/min during the
night. PRN medications to treat side effects
were ordered prior to drug administration.
Medication Oral treprostinil Total 
IV 
epoprostenol
Day 1 Dose: 
0.25 mg/p.o./H.S. 0.375 mg 4 ng/kg/min









3.75 mg 3 ng/kg/min




6.5 mg 2 ng/kg/min












home with specialty 
pharmacy to 
continue further oral 
titreation.
9 mg 0 ng/kg/min
